Erlotinib and gastric acid-reducing agents: a combination to avoid or to support?

Young Hak Kim, Katsuhiro Masago, Michiaki Mishima, Erlotinib and Gastrointestinal Ulcer Journal of Thoracic Oncology. ,vol. 5, pp. 1108- 1109 ,(2010) , 10.1097/JTO.0B013E3181E07F29

Masahide Fukudo, Yasuaki Ikemi, Yosuke Togashi, Katsuhiro Masago, Young Hak Kim, Tadashi Mio, Tomohiro Terada, Satoshi Teramukai, Michiaki Mishima, Ken-ichi Inui, Toshiya Katsura, Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer Clinical Pharmacokinectics. ,vol. 52, pp. 593- 609 ,(2013) , 10.1007/S40262-013-0058-5

L Zhang, F Wu, S C Lee, H Zhao, L Zhang, pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development. Clinical Pharmacology & Therapeutics. ,vol. 96, pp. 266- 277 ,(2014) , 10.1038/CLPT.2014.87

J.F. Hilton, D. Tu, L. Seymour, F.A. Shepherd, P.A. Bradbury, An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib Lung Cancer. ,vol. 82, pp. 136- 142 ,(2013) , 10.1016/J.LUNGCAN.2013.06.008